Tenuigenin inhibits RANKL-induced osteoclastogenesis by down-regulating NF-κB activation and suppresses bone loss in vivo

Biochemical and Biophysical Research Communications

Volumn 466, Issue 4, 2015, Pages 615-621

  Yang, Shuo ^a,b   Li, Xianan ^b   Cheng, Liang ^a   Wu, Hongwei ^b   Zhang, Can ^a   Li, Kanghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

NF B; Osteoclasts; Osteolysis; RANKL; Tenuigenin

Indexed keywords

AGENTS AFFECTING CELL DIVISION; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TENUIGENIN; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BONE DESTRUCTION; CELL VIABILITY ASSAY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; POLYGALA TENUIFOLIA; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; DRUG THERAPY; METABOLISM; OSTEOCLAST; PATHOLOGY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; DOWN-REGULATION; DRUGS, CHINESE HERBAL; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND;

EID: 84943249244     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.09.093     Document Type: Article

References (29)

1. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
2. D. Lacey, E. Timms, H.-L. Tan, M. Kelley, C. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, and S. Scully Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
3. H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S.-i. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, and A. Murakami Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc. Natl. Acad. Sci. 95 1998 3597 3602
4. Y.-Y. Kong, H. Yoshida, I. Sarosi, H.-L. Tan, E. Timms, C. Capparelli, S. Morony, A.J. Oliveira-dos-Santos, G. Van, and A. Itie OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
5. M.L. Chaisson, D.G. Branstetter, J.M. Derry, A.P. Armstrong, M.E. Tometsko, K. Takeda, S. Akira, and W.C. Dougall Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α J. Biol. Chem. 279 2004 54841 54848
6. S. Dai, T. Hirayama, S. Abbas, and Y. Abu-Amer The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis J. Biol. Chem. 279 2004 37219 37222
7. L. Xing, T.P. Bushnell, L. Carlson, Z. Tai, M. Tondravi, U. Siebenlist, F. Young, and B.F. Boyce NF-κB p50 and p52 Expression Is Not Required for RANK-Expressing Osteoclast Progenitor Formation but Is Essential for RANK-and Cytokine-Mediated Osteoclastogenesis J. Bone Min. Res. 17 2002 1200 1210
8. D. Krappmann, E.N. Hatada, S. Tegethoff, J. Li, A. Klippel, K. Giese, P.A. Baeuerle, and C. Scheidereit The IκB kinase (IKK) complex is tripartite and contains IKKγ but not IKAP as a regular component J. Biol. Chem. 275 2000 29779 29787
9. M.G. Ruocco, S. Maeda, J.M. Park, T. Lawrence, L.-C. Hsu, Y. Cao, G. Schett, E.F. Wagner, and M. Karin IκB kinase (IKK) β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss J. Exp. Med. 201 2005 1677 1687
10. V. Iotsova, J. Caamaño, J. Loy, Y. Yang, A. Lewin, and R. Bravo Osteopetrosis in mice lacking NF-κB1 and NF-κB2 Nat. Med. 3 1997 1285 1289
11. S. Vaira, M. Alhawagri, I. Anwisye, H. Kitaura, R. Faccio, and D.V. Novack RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice J. Clin. Invest. 118 2008 2088
12. C.H. Park, S.H. Choi, J.W. Koo, J.H. Seo, H.S. Kim, S.J. Jeong, and Y.H. Suh Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11 J. Neurosci. Res. 70 2002 484 492
13. H.L. Yuan, B. Li, J. Xu, Y. Wang, Y. He, Y. Zheng, and X.M. Wang Tenuigenin protects dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharide CNS Neurosci. Ther. 18 2012 584 590
14. H. Zhang, T. Han, L. Zhang, C.-H. Yu, D.-G. Wan, K. Rahman, L.-P. Qin, and C. Peng Effects of tenuifolin extracted from radix polygalae on learning and memory: a behavioral and biochemical study on aged and amnesic mice Phytomedicine 15 2008 587 594
15. M. Kogawa, K. Hisatake, G.J. Atkins, D.M. Findlay, Y. Enoki, T. Sato, P.C. Gray, Y. Kanesaki-Yatsuka, P.H. Anderson, and S. Wada The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation J. Biol. Chem. 288 2013 31299 31312
16. W. Zou, T. Izawa, T. Zhu, J. Chappel, K. Otero, S.J. Monkley, D.R. Critchley, B.G. Petrich, A. Morozov, and M.H. Ginsberg Talin1 and Rap1 are Critical for Osteoclast Function Mol. Cell. Biol. 33 2013 830 844
17. C. Wang, J.H. Steer, D.A. Joyce, K.H. Yip, M.H. Zheng, and J. Xu 12-O-tetradecanoylphorbol-13-acetate (TPA) Inhibits Osteoclastogenesis by Suppressing RANKL-Induced NF-κB Activation J. Bone Min. Res. 18 2003 2159 2168
18. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
19. L. He, J. Lee, J.H. Jang, S.-H. Lee, M.H. Nan, B.-C. Oh, S.G. Lee, H.H. Kim, N.K. Soung, and J.S. Ahn Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos Bone 50 2012 1207 1213
20. M. Asagiri, and H. Takayanagi The molecular understanding of osteoclast differentiation Bone 40 2007 251 264
21. J. Gohda, T. Akiyama, T. Koga, H. Takayanagi, S. Tanaka, and J.i. Inoue RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis EMBO J. 24 2005 790 799
22. S. Khosla Minireview: the opg/rankl/rank system Endocrinology 142 2001 5050 5055
23. L.J. Egan, D.C. Mays, C.J. Huntoon, M.P. Bell, M.G. Pike, W.J. Sandborn, J.J. Lipsky, and D.J. McKean Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity J. Biol. Chem. 274 1999 26448 26453
24. E. Kopp, and S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
25. M.-J. Yin, Y. Yamamoto, and R.B. Gaynor The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β Nature 396 1998 77 80
26. J.A. Keifer, D.C. Guttridge, B.P. Ashburner, and A.S. Baldwin Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity J. Biol. Chem. 276 2001 22382 22387
27. A. Rossi, P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M.G. Santoro Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase Nature 403 2000 103 118
28. M. Karin, Y. Yamamoto, and Q.M. Wang The IKK NF-κB system: a treasure trove for drug development Nat. Rev. Drug Discov. 3 2004 17 26
29. E. Ang, N.J. Pavlos, S.L. Rea, M. Qi, T. Chai, J.P. Walsh, T. Ratajczak, M.H. Zheng, and J. Xu Proteasome inhibitors impair RANKL-induced NF-κB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IκBα signaling cascades J. Cell. Physiol. 220 2009 450 459